Product Details
Additional Information
| Product Name | Mounjaro 5 Mg/0.5 Ml Pen |
| Application | Type 2 Diabetes Treatment |
| Active Ingredient | Tirzepatide |
| Mechanism of Action | Dual GIP and GLP-1 receptor agonist; enhances insulin secretion, reduces glucagon levels, and slows gastric emptying |
| Strength | 5 mg/0.5 mL |
| Administration Route | Subcutaneous |
| Common Side Effects | Nausea, vomiting, diarrhea, reduced appetite, abdominal pain |
| Storage Conditions | Refrigerate at 2°C to 8°C (36°F to 46°F); may be stored at room temperature (=30°C or 86°F) for up to 21 days |
| Injection Sites | Abdomen, thigh, or upper arm (rotate sites to prevent irritation) |
| Frequency of Use | Once weekly |
| Needle Feature | Automatic needle retraction for safety |
| Packaging | Single-use, disposable prefilled pen |
| Usage Restrictions | Not for use in patients with type 1 diabetes or diabetic ketoacidosis |
| Indications | Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes |
Description
Mounjaro (tirzepatide) 5 mg/0.5 mL is a once-weekly injectable medication used for the treatment of type 2 diabetes mellitus. It is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. By mimicking the effects of these incretin hormones, it enhances insulin secretion, suppresses glucagon levels, and slows gastric emptying, leading to improved glycemic control.
The prefilled pen delivers a fixed dose of 5 mg tirzepatide in 0.5 mL solution. It is designed for patient self-administration and features an automatic needle retraction system to enhance safety. Injection sites include the abdomen, thigh, or upper arm, with rotation recommended to avoid irritation. The medication should not be used in patients with a history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.
Common side effects include nausea, vomiting, diarrhea, decreased appetite, and abdominal pain. Severe adverse reactions may include pancreatitis, hypoglycemia when combined with insulin or sulfonylureas, and hypersensitivity reactions. Regular monitoring of blood glucose and kidney function is recommended during treatment.
Frequently Asked Questions (FAQs)
The cost of Mounjaro 5 Mg/0.5 ML Pen is $available for registerd members only
Mounjaro 5 Mg/0.5 ML Pen is manufactured by Eli Lilly.
You can purchase Mounjaro 5 Mg/0.5 ML Pen on our website at https://supplies.pipelinemedical.com/product/detail/mounjaro-5-mg-0-5-ml-pen-635567